Morningstar Investor users sign in here.
TOPIC

PATHOLOGY News & Analysis

Market is underestimating ASX pathology shares
Stocks
Market is underestimating ASX pathology shares
Morningstar sees several reasons to expect a stronger recover than market consensus.
Shane Ponraj | 20 May 2024
Healius takeover bid may face resistance from board and regulators
Stocks
Healius takeover bid may face resistance from board and regulators
The proposed deal to create Australia’s largest pathology provider faces hurdles from the Healius board and regulators, says Morningstar.
Joshua Peach | 20 March 2023